Tesamorelin Makes Fat Healthier, Not Just Less
Tesamorelin improves fat quality independent of changes in fat quantity
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study found that a drug called tesamorelin not only reduces belly fat in people with HIV, but also makes the fat healthier. Healthier fat is denser, smaller, and less inflamed. The drug made fat denser in both belly and under-the-skin areas, and this was linked to better blood markers like...
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 570 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study found that a drug called tesamorelin not only reduces belly fat in people with HIV, but also makes the fat healthier. Healthier fat is denser, smaller, and less inflamed. The drug made fat denser in both belly and under-the-skin areas, and this was linked to better blood markers like...
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 570 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Publication
Authors
Lake JE, La K, Erlandson KM, Adrian S, Yenokyan G, Scherzinger A, Dubé MP, Stanley T, Grinspoon S, Falutz J, Mamputu JC, Marsolais C, McComsey GA, Brown TT
Related Content
Claims (7)
Tesamorelin independently increases fat density in visceral and subcutaneous adipose tissue, indicating improved fat quality with smaller adipocytes, better vascularization, reduced hypoxia, and decreased inflammation, independent of fat quantity changes.
For HIV patients with excess belly fat who responded to the drug tesamorelin, taking the drug for 26 weeks made the fat around their organs denser by 2.3 points on a CT scan scale, even after accounting for changes in fat amount, which suggests the fat became healthier.
The same HIV patients with belly fat who responded to tesamorelin also saw their under-the-skin fat become denser by 3.5 points on CT scans after 26 weeks, regardless of fat amount changes, indicating healthier fat tissue.
When HIV patients on tesamorelin had denser belly fat, their bodies also produced more adiponectin, a hormone that helps regulate metabolism, showing a link between fat quality and metabolic health.
Denser under-the-skin fat in HIV patients on tesamorelin was linked to higher levels of the metabolism-regulating hormone adiponectin, suggesting improved fat function.